> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Glaxo Files BLA for Shingles Vaccine
- URL: https://www.fdaweb.com/glaxo-files-bla-for-shingles-vaccine/
- Published: 2016-10-23T12:00:00.000Z
- Updated: 2026-09-14T21:41:45.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137154

GlaxoSmithKline has submitted a BLA for its Shingrix vaccine and its use for preventing herpes zoster (shingles) in people aged 50 years and older. The submission is based on data from a Phase 3 clinical trial program which showed that by reducing the incidence of shingles, the candidate vaccine also reduced the overall incidence of postherpetic neuralgia, a form of chronic pain associated with shingles. Approval is being sought for the vaccine to be given intramuscularly in two doses, with a two- to six-month interval between each.